MX2018003006A - Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota. - Google Patents

Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.

Info

Publication number
MX2018003006A
MX2018003006A MX2018003006A MX2018003006A MX2018003006A MX 2018003006 A MX2018003006 A MX 2018003006A MX 2018003006 A MX2018003006 A MX 2018003006A MX 2018003006 A MX2018003006 A MX 2018003006A MX 2018003006 A MX2018003006 A MX 2018003006A
Authority
MX
Mexico
Prior art keywords
compound
gout
treating
preventing hyperuricemia
hyperuricemia
Prior art date
Application number
MX2018003006A
Other languages
English (en)
Inventor
Jie Wen
Shi Dongfang
Cheng Xi
Zhu Jianghua
Gu Jie
FU Changjin
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Publication of MX2018003006A publication Critical patent/MX2018003006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

La invención describe una clase de compuestos para tratar o prevenir la hiperuricemia o gota, que es un compuesto mostrado en la fórmula general (I) o una sal farmacéuticamente aceptable. Estos compuestos y sus sales farmacéuticamente aceptables en la invención son útiles para la promoción de la excreción de ácido úrico para tratar o prevenir la hiperuricemia o la gota.
MX2018003006A 2015-09-10 2016-09-08 Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota. MX2018003006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
PCT/CN2016/098468 WO2017041732A1 (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物

Publications (1)

Publication Number Publication Date
MX2018003006A true MX2018003006A (es) 2018-08-09

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003006A MX2018003006A (es) 2015-09-10 2016-09-08 Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.

Country Status (26)

Country Link
US (1) US10399971B2 (es)
EP (1) EP3348557B1 (es)
JP (1) JP6635527B2 (es)
KR (1) KR102109061B1 (es)
CN (1) CN106432229B (es)
AU (1) AU2016320073B2 (es)
BR (1) BR112018004863B1 (es)
CA (1) CA2998034C (es)
CY (1) CY1123137T1 (es)
DK (1) DK3348557T3 (es)
EA (1) EA037280B1 (es)
ES (1) ES2803223T3 (es)
HR (1) HRP20201094T1 (es)
HU (1) HUE051448T2 (es)
IL (1) IL257960A (es)
LT (1) LT3348557T (es)
MX (1) MX2018003006A (es)
MY (1) MY195675A (es)
NZ (1) NZ741318A (es)
PL (1) PL3348557T3 (es)
PT (1) PT3348557T (es)
RS (1) RS60697B1 (es)
SG (1) SG11201802010QA (es)
SI (1) SI3348557T1 (es)
TW (1) TWI681772B (es)
WO (1) WO2017041732A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018214961A1 (zh) * 2017-05-26 2018-11-29 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN114213331A (zh) * 2017-05-26 2022-03-22 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
JP7266901B2 (ja) * 2018-01-19 2023-05-01 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物、調製方法及びその医薬的な応用
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) * 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
TW202342456A (zh) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 可用於降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
US10005750B2 (en) * 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound

Also Published As

Publication number Publication date
NZ741318A (en) 2019-03-29
EA201890694A1 (ru) 2018-10-31
SI3348557T1 (sl) 2020-09-30
TW201808284A (zh) 2018-03-16
CN106432229A (zh) 2017-02-22
BR112018004863A2 (es) 2018-10-02
US20180282321A1 (en) 2018-10-04
PL3348557T3 (pl) 2020-11-16
HRP20201094T1 (hr) 2020-10-30
KR102109061B1 (ko) 2020-05-11
CA2998034A1 (en) 2017-03-16
CA2998034C (en) 2021-05-04
TWI681772B (zh) 2020-01-11
PT3348557T (pt) 2020-08-03
CY1123137T1 (el) 2021-10-29
IL257960A (en) 2018-05-31
RS60697B1 (sr) 2020-09-30
JP6635527B2 (ja) 2020-01-29
JP2018526417A (ja) 2018-09-13
HUE051448T2 (hu) 2021-03-01
KR20180044426A (ko) 2018-05-02
EP3348557A4 (en) 2019-03-06
LT3348557T (lt) 2020-08-10
MY195675A (en) 2023-02-03
AU2016320073A1 (en) 2018-04-26
EA037280B1 (ru) 2021-03-03
SG11201802010QA (en) 2018-04-27
EP3348557A1 (en) 2018-07-18
EP3348557B1 (en) 2020-04-29
AU2016320073B2 (en) 2019-05-09
DK3348557T3 (da) 2020-07-20
BR112018004863B1 (pt) 2023-04-18
US10399971B2 (en) 2019-09-03
WO2017041732A1 (zh) 2017-03-16
ES2803223T3 (es) 2021-01-25
CN106432229B (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
NZ741318A (en) Compound for treating or preventing hyperuricemia or gout
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
NZ733174A (en) Quinazoline derivatives used to treat hiv
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
NZ703064A (en) Inhibitors of hepatitis c virus
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
TW201613864A (en) Novel compounds
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
AU2015280874A1 (en) Novel heterocyclic compound
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.

Legal Events

Date Code Title Description
FG Grant or registration